Stock Taper
SCREENER COMPARE ANY 2 STOCKS
IMNM
IMMUNOME, INC.
NASDAQ
$27.57
▼ DOWN 4.50% (-1.30)

KEY STATISTICS

Market Cap$2.64 B
52w High$30.06
52w Low$8.66
Dividend Yield—
Frequency—
P/E-10.90
Volume783.50K
Shares Out.95.60M

COMPANY

LEADERSHIP

Clay Siegall
CHIEF EXECUTIVE
Clay Siegall

COMPENSATION 2026

Salary$735,000
Stock Awards$0
Incentive Plan Pay$661,500
All Other Comp.$13,291
Total$7,682,601

ABOUT

SECTOR
Healthcare
WENT PUBLIC
October 2, 2020
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
247

PRICE TARGET

Target High$37.00
Target Low$33.00
Target Median$35.50
Target Consensus$35.25

UPCOMING EARNINGS

DateNov 5, 2026
DayThursday
Rev. Est.$181.82K
NOV
5
THU

PRICE

$27.57 ▼ DOWN 4.50% (−$1.30)
$27.60$28.00$28.409:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM27.57

About Immunome, Inc.

https://www.immunome.com ↗

Immunome, Inc. is a biopharmaceutical company developing antibody therapeutics for cancer and infectious diseases, including IMM-ONC-01 targeting IL-38 and IMM-BCP-01 for COVID-19, based in Exton, Pennsylvania.

INDUSTRY

Biotechnology

A PRODUCT IMMUNOME, INC. IS KNOWN FOR

varegacestat
varegacestat

Immunome's late-stage, once-daily oral gamma secretase inhibitor for desmoid tumors is in Phase 3 trials, with topline data expected in late 2025.

COMPETITORS

COMPETITOR
BIIB COMPARE
LLY COMPARE
MRK COMPARE
PFE COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
136
LISTED HERE
26
RANKED BY POSITION SIZE
VTI
0.00% · 3.2M
XBI
0.77% · 3.2M
XSU.TO
0.10% · 2.7M
SCHA
0.06% · 506.9K
CANC
3.01% · 231.0K
SBIO
1.60% · 139.6K
LABU
0.53% · 116.0K
DFAS
0.02% · 105.8K
XRSU.L
0.10% · 96.4K
RSSL
0.10% · 50.3K
FHLC
0.04% · 44.3K
WDNA.L
2.67% · 31.3K
BBSC
0.11% · 28.3K
GSSC
0.07% · 27.9K
FSCC
0.17% · 19.4K
BBC
0.94% · 17.1K
ARWG
2.27% · 15.6K
PRFZ
0.01% · 10.5K
MMSC
0.48% · 8.8K
SGRW
0.85% · 8.7K
RTWP.L
0.09% · 6.8K
URTY
0.04% · 4.3K
RFLR
0.11% · 3.8K
STXK
0.12% · 3.6K
TILT
0.00% · 2.8K
VETS
0.18% · 2.4K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
92.22%
HOLDERS
240
TOP 12 OF 240 · RANKED BY POSITION SIZE
Fmr LLC
17.0M sh · $371.13M
T. Rowe Price Investment Management, Inc.
16.4M sh · $357.88M
Blackrock, Inc.
8.2M sh · $178.65M
Point72 Asset Management, L.P.
7.0M sh · $151.11M
Vanguard Group Inc
6.0M sh · $129.71M
Redmile Group, LLC
5.7M sh · $122.83M
State Street Corp
5.4M sh · $118.1M
Primecap Management Co/Ca/
4.8M sh · $104.72M
Enavate Sciences Gp, LLC
4.8M sh · $102.43M
Wellington Management Group Llp
4.7M sh · $103.49M
Driehaus Capital Management LLC
4.1M sh · $89.66M
Ecor1 Capital, LLC
4.1M sh · $47.77M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book2
Overall Score2

INSIDER TRADES

★
DIRECTOR
Barchas Isaac
Sale · 11.0K shares
2026-08-12
★
DIRECTOR
Barchas Isaac
Sale · 10.1K shares
2026-08-10
★
DIRECTOR
Barchas Isaac
Sale · 62.3K shares
2026-08-11
★
DIRECTOR
Barchas Isaac
Sale · 20.8K shares
2026-08-06

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 5
OUTPERFORM 3
OVERWEIGHT 1
9 GRADES IN THE LAST 12 MONTHS
Wedbush OUTPERFORM Truist Securities BUY Leerink Partners OUTPERFORM HC Wainwright & Co. BUY Craig-Hallum BUY Stephens & Co. OVERWEIGHT Evercore ISI Group OUTPERFORM Guggenheim BUY

SECTORS PEERS

PEERPRICE
SYRE$90.36COMPARE
ABCL$11.35COMPARE
CLDX$39.12COMPARE
PHVS$35.32COMPARE
VERA$34.19COMPARE
BHVN$15.41COMPARE
ZBIO$31.27COMPARE
NTLA$12.87COMPARE